RE:RE:ACB SP without CMEDOn a cost per patient basis, this deal is better than the $430M share bought deal that took place between Canopy and Mettrum. Also, Mettrum screwed Canopy after the deal went through when it was discovered that they were using banned substances to grow their weed resulting in a class action lawsuit that is still not over with.
They can raise the offer to $26 cap and I would not be worried at all. ACB is a beast and if you don't realize this now, you will this summer and will be greatly disappointed if you choose to sell now.
But it's your life and your own choice to make. Good luck